Sign inJoin waitlistJoin the waitlist

Terence Friedlander

Professor & Chief · University of California (San Francisco) School of Medicine

Credentials: · · ·

History

University of California-San Francisco
2010–2011
New York University
1999–2003
Brown University
1995–1999
Internal Medicine
Brown University
1996–1999

Research

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
JAMA Oncology · 2017 · 722 citations
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
Cell · 2020 · 612 citations
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
Cell · 2020 · 603 citations

Eric Small
23 papers
CR
Charles Ryan
21 papers
Lawrence Fong
21 papers
Rahul Aggarwal
21 papers
Vadim Koshkin
21 papers
Jonathan Chou
18 papers · 4 as a fellow
Sima Porten
13 papers
Christopher Hoimes
11 papers
Thomas Flaig
11 papers
Hala Borno
10 papers · 10 as a fellow
Daniel Kwon
9 papers · 4 as a fellow
Felix Feng
9 papers

Clinical trials

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
Principal investigator · Withdrawn · Phase 2
University of California, San Francisco
2018–2022
Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
Principal investigator · Withdrawn · Phase 1
University of California, San Francisco
2018–2020
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
Principal investigator · Withdrawn · Phase 2
Terence Friedlander, MD
2017–2024
Ketoconazole and Dexamethasone in Prostate Cancer
Principal investigator · Completed · Phase 2
University of California, San Francisco
2009–2014